FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to pulmonology. The patient's blood is analysed for CD3+ CD 16-, CD19+CD23+, CD45RA+CD4+/CD45RO+CD4+, a zymozan stimulated nitro blue tetrazolium test (NBT-induced test), a nitro blue tetrazolium reduction test (NBT-spontaneous test), a phytohemagglutinin response are carried out. If CD3+CD16- exceeds 1.85*10^3, CD45RA+CD4+/CD45RO+CD4+ is lower than 0.85, NBT-induced test is higher than 38%, lung cancer is diagnosed. The values CD19+CD23+ lower than 0.07*10^3, phytohemagglutinin response lower than 2.1, NBT-spontaneous test lower than 7% indicate lung abscess.
EFFECT: technique allows for precise differentiation of said diseases; it is safe and technologically feasible.
2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PREDICTING LUNG CANCER ARISING IN PATIENTS WITH CHRONIC OBSTRUCTIVE LUNG DISEASE | 2009 |
|
RU2407013C1 |
| METHOD OF PREDICTING BEGINNING OF CHRONIC OBSTRUCTIVE LUNG DISEASE | 2009 |
|
RU2407012C1 |
| METHOD OF PREDICTING DEVELOPMENT OF LUNG ABSCESS IN CASE OF CHRONIC OBSTRUCTIVE LUNG DISEASE | 2009 |
|
RU2407010C1 |
| METHOD FOR PREDICTION OF STAGE OF MULTIPLE SCLEROSIS TAKING INTO ACCOUNT VALUES OF IMMUNOLOGICAL STATUS | 2013 |
|
RU2528882C1 |
| METHOD FOR PREDICTION OF DEVELOPING MULTIPLE SCLEROSIS TAKING INTO ACCOUNT IMMUNE-METABOLIC VALUES | 2013 |
|
RU2528879C1 |
| METHOD OF PREDICTING STAGE OF MULTIPLE SCLEROSIS TAKING INTO ACCOUNT INDICATORS OF IMMUNOLOGICAL STATUS | 2023 |
|
RU2811481C1 |
| METHOD FOR PREDICTION OF LIFE EXPECTANCY IN PATIENTS WITH METASTATIC TUMORS | 2023 |
|
RU2821659C1 |
| METHOD FOR DETERMINING AND ASSESSING LOCAL IMMUNITY IN PATIENTS WITH PSORIASIS | 2022 |
|
RU2804243C1 |
| METHOD FOR PREDICTION OF RATE OF ACUTE INFECTIOUS DISEASES IN INFANTS | 2010 |
|
RU2431147C1 |
| METHOD OF DIFFERENTIAL DIAGNOSTICS OF TUBERCULOSIS AND CHRONIC NON-SPECIFIC PULMONARY DISEASES | 0 |
|
SU1483365A1 |
